Hepatobiliary cancer represents a group of serious malignancies affecting the liver, bile ducts, gallbladder, and pancreas—organs central to digestion and waste processing. Treatment approaches vary widely based on cancer type, stage, and individual patient factors, combining established medical interventions with promising research into new therapies.

Understanding Treatment Goals for Hepatobiliary Cancer

When someone receives a diagnosis of hepatobiliary cancer, the path forward depends on many individual factors. The main goal of treatment is often to control the disease, slow its progression, and help patients maintain the best possible quality of life. Because hepatobiliary cancers include several different types—such as hepatocellular carcinoma (cancer starting in liver cells), cholangiocarcinoma (bile duct cancer), gallbladder cancer, and pancreatic cancer—each person’s treatment plan must be carefully tailored to their specific situation.^[1][2]

The treatment approach depends heavily on the tumor’s grade and stage, meaning how aggressive the cancer appears under a microscope and how far it has spread in the body. It also depends on how well the liver is functioning, since many patients with hepatobiliary cancers already have underlying liver conditions such as cirrhosis (scarring of the liver) or chronic hepatitis B or C infection. Patient preferences and overall health status play crucial roles in deciding which treatments to pursue.^[13]

Medical societies and cancer organizations have developed standard treatment guidelines based on years of research and clinical experience. At the same time, researchers continue to investigate new therapies through clinical trials. These studies test innovative approaches that may one day become standard care. For anyone diagnosed with hepatobiliary cancer, participating in a clinical trial is often considered the preferred option when available, as it provides access to cutting-edge treatments while contributing to medical knowledge that can help future patients.^[2][10]

Standard Treatment Approaches

Standard treatments for hepatobiliary cancers have been refined over decades and represent the foundation of care for most patients. The specific combination of treatments varies greatly depending on whether the cancer is detected early, whether it can be removed surgically, and whether it has spread to other parts of the body.

Surgery

Surgery remains one of the most important treatment options when hepatobiliary cancer is found early and hasn’t spread beyond its original location. For liver cancer, surgeons may perform a partial hepatectomy, which means removing the part of the liver containing the tumor along with some healthy tissue around it. The liver has a remarkable ability to regenerate, so the remaining healthy tissue can often take over the liver’s functions and may even grow back to a larger size over time.^[9]

In carefully selected cases, a complete liver transplant may be recommended. This involves removing the entire diseased liver and replacing it with a healthy donated liver. Liver transplant is typically considered when the cancer is confined to the liver, hasn’t spread to blood vessels or other organs, and the patient meets specific medical criteria. Because donor livers are scarce, patients may wait months or even longer for a suitable organ. During this waiting period, other treatments are often given to keep the cancer under control.^[9][13]

For bile duct and gallbladder cancers, surgery may involve removing portions of the bile duct system, the gallbladder, and sometimes parts of the liver or pancreas, depending on where the tumor is located and how extensive it is. These surgeries can be complex and require experienced surgical teams at specialized medical centers.^[15]

Ablation Therapy

Ablation therapy uses various forms of energy to destroy cancer cells without removing tissue surgically. This approach is particularly useful for patients who cannot undergo surgery due to poor liver function, the tumor’s location, or other health concerns. Radiofrequency ablation involves inserting special needles directly into the tumor, either through the skin or during a surgical procedure. These needles deliver high-energy radio waves that heat the tumor tissue, killing the cancer cells.^[9]

Microwave ablation works similarly but uses microwave energy to create high temperatures that damage and destroy cancer cells. This technique can sometimes treat larger tumors or tumors in difficult locations. Another ablation method, percutaneous ethanol injection, involves injecting pure alcohol directly into small liver tumors. The alcohol kills cancer cells by dehydrating them. This approach is typically used for smaller tumors and may require several treatment sessions. Local anesthesia is usually sufficient, though general anesthesia may be used if multiple tumors need treatment.^[9][14]

Cryoablation, also called cryotherapy or cryosurgery, takes the opposite approach by using extreme cold to freeze and destroy cancer cells. A special probe is inserted into the tumor, and the tissue is frozen to temperatures that cancer cells cannot survive. Ultrasound imaging often guides the placement of these instruments to ensure accurate targeting.^[9]

Embolization Therapy

Embolization therapy takes advantage of how liver tumors receive their blood supply. While healthy liver tissue gets most of its blood from the portal vein, liver tumors primarily receive blood from the hepatic artery. By blocking or reducing blood flow through the hepatic artery, doctors can starve the tumor of oxygen and nutrients while preserving healthy liver tissue.^[9]

Transarterial embolization (TAE) involves threading a thin, flexible tube called a catheter through a small cut in the inner thigh. The catheter is guided through blood vessels until it reaches the hepatic artery. Once in position, the doctor injects substances that block the artery, cutting off the tumor’s blood supply. Transarterial chemoembolization (TACE) combines this approach with chemotherapy. The anticancer drugs can be attached to tiny beads that are injected into the hepatic artery, or the drugs can be injected directly. This delivers high concentrations of chemotherapy directly to the tumor while limiting exposure to the rest of the body, which can reduce side effects.^[9][14]

These procedures are typically used for patients who cannot have surgery and whose cancer hasn’t spread outside the liver. They may help shrink tumors, control symptoms, and potentially extend survival. Multiple treatment sessions are often needed over time.

Radiation Therapy

Radiation therapy uses high-energy waves similar to x-rays to kill cancer cells. Traditional external beam radiation has historically been challenging for liver cancer because the liver can be easily damaged by radiation, and the liver moves with breathing. However, newer techniques have made radiation safer and more effective.^[11][13]

A specialized form called selective internal radiation therapy (SIRT) delivers radiation from inside the body. Tiny radioactive beads are injected into the blood vessels feeding the liver tumor. These beads lodge in the small vessels around the tumor and deliver radiation directly to the cancer cells while sparing most of the healthy liver tissue. This treatment is sometimes used for adults whose liver hasn’t been too badly damaged and whose cancer cannot be removed by surgery.^[11]

Systemic Chemotherapy

Chemotherapy uses medicines to kill rapidly dividing cancer cells throughout the body. For hepatobiliary cancers, chemotherapy is often reserved for situations where the cancer has spread beyond the liver or cannot be treated with surgery or local therapies. Different chemotherapy drugs may be used depending on the specific type of hepatobiliary cancer.^[13]

Chemotherapy is typically given in cycles, with treatment periods followed by rest periods to allow the body to recover. The duration of treatment varies but may continue for several months or longer, depending on how well the cancer responds and how well the patient tolerates the side effects.

Targeted Therapy

Targeted cancer drugs are designed to interfere with specific molecules involved in tumor growth and survival. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapies aim to attack cancer cells more precisely. For liver cancer, several targeted drugs have been approved that work by blocking signals that promote tumor growth or by interfering with the development of new blood vessels that tumors need to grow. These medications are typically given as pills taken daily at home.^[13][14]

Targeted therapies are often used for advanced hepatobiliary cancers that cannot be removed by surgery or that have spread to other parts of the body. They may be given alone or in combination with other treatments. While these drugs can help slow cancer growth and manage symptoms, they don’t work for everyone, and they can cause various side effects that need monitoring.

Side Effects of Standard Treatments

All cancer treatments can cause side effects, though not everyone experiences the same ones or to the same degree. Surgical procedures carry risks such as bleeding, infection, and complications related to anesthesia. Recovery from liver surgery can take several weeks or months, and patients may experience pain, fatigue, and temporary changes in liver function.

Ablation therapies may cause temporary discomfort at the treatment site, fever, and sometimes complications if the heat or cold affects nearby organs or blood vessels. Embolization procedures can cause pain in the upper right abdomen, fever, nausea, and temporary liver dysfunction—a cluster of symptoms sometimes called “post-embolization syndrome” that typically resolves within a week or two.

Chemotherapy side effects vary depending on which drugs are used but commonly include fatigue, nausea, vomiting, diarrhea, mouth sores, hair loss, and increased risk of infection due to low white blood cell counts. Targeted therapies often cause skin rashes, diarrhea, high blood pressure, hand-foot syndrome (redness, swelling, and pain on palms and soles), and fatigue.

Healthcare teams work closely with patients to manage these side effects through supportive medications, dietary adjustments, and lifestyle modifications. Many side effects can be significantly reduced with proper management, allowing patients to continue their treatment plans.

Treatment in Clinical Trials

Clinical trials represent the frontier of cancer treatment, testing new drugs, new combinations of existing treatments, and innovative approaches that may become tomorrow’s standard care. For hepatobiliary cancers, which remain challenging to treat, clinical trials offer hope for better outcomes and are actively investigating multiple promising strategies.

Immunotherapy Approaches

Immunotherapy has revolutionized cancer treatment in recent years by harnessing the power of the patient’s own immune system to fight cancer. The immune system normally identifies and destroys abnormal cells, but cancer cells often develop ways to hide from or suppress immune responses. Immunotherapy drugs work to overcome these evasion strategies.

Several immunotherapy drugs are being tested for hepatobiliary cancers in clinical trials. One important class called immune checkpoint inhibitors works by blocking proteins that cancer cells use to “turn off” immune responses. When these checkpoint proteins are blocked, immune cells can recognize and attack the cancer more effectively. Some of these immunotherapy drugs have already shown promising results and received regulatory approval for certain patients with advanced liver cancer, particularly when combined with other treatments.^[14]

Clinical trials are exploring various immunotherapy combinations, such as pairing checkpoint inhibitors with targeted drugs that block tumor blood vessel formation. Early results from some of these combination trials have shown improved survival and tumor shrinkage compared to older treatments. Researchers are also investigating which patients are most likely to benefit from immunotherapy, as response rates vary significantly between individuals.

Novel Targeted Therapies

Researchers continue to identify new molecular targets that drive hepatobiliary cancer growth. Clinical trials are testing drugs that interfere with specific genetic mutations, abnormal proteins, or signaling pathways found in these cancers. Some trials focus on rare but specific genetic alterations, such as mutations in genes called FGFR2 or IDH1, which occur in subsets of bile duct cancers. Drugs designed to block these mutated proteins have shown encouraging results in early-phase trials.

Other investigational targeted drugs aim to overcome resistance that often develops to existing therapies. Cancer cells are remarkably adaptable and can find alternative growth pathways when one route is blocked. By understanding these resistance mechanisms, scientists develop drugs that can block multiple pathways simultaneously or that work through entirely different mechanisms.

Phase I, II, and III Trials

Clinical trials proceed through carefully designed phases, each with specific goals. Phase I trials primarily focus on safety. They determine the best dose of a new treatment, identify side effects, and gather preliminary information about whether the treatment shows any anti-cancer activity. These trials typically involve small numbers of patients, often those whose cancer has not responded to standard treatments.

Phase II trials enroll more patients and focus on determining whether the treatment is effective against specific cancer types. Researchers measure how many patients experience tumor shrinkage, how long the treatment controls the cancer, and continue to monitor safety. Phase II results help decide whether a treatment is promising enough to move forward to larger studies.

Phase III trials are large studies that compare the new treatment directly against current standard treatments. These trials provide the definitive evidence needed to determine whether the new approach is better than existing options. Patients are randomly assigned to receive either the new treatment or standard care, and outcomes such as survival, quality of life, and side effects are carefully tracked over time.

Trial Locations and Eligibility

Clinical trials for hepatobiliary cancers are conducted at major cancer centers worldwide, including locations in the United States, Europe, and increasingly in other regions. Eligibility criteria vary by trial but typically consider factors such as the specific type and stage of cancer, previous treatments received, liver function tests, overall health status, and sometimes the presence or absence of specific genetic markers in the tumor.

Patients interested in clinical trials should discuss options with their healthcare team. Many cancer centers have dedicated research coordinators who can help identify appropriate trials and explain the enrollment process. Some trials cover treatment costs, while others may require insurance coverage of standard care components.

Combination Approaches Under Investigation

Many current clinical trials investigate combinations of different treatment types. For example, some studies test whether adding immunotherapy or targeted drugs to local treatments like ablation or embolization can improve outcomes. The rationale is that destroying tumor tissue through local therapy might release tumor-specific proteins that help the immune system recognize and attack any remaining cancer cells throughout the body.

Other trials explore the optimal sequence of treatments—whether it’s better to give immunotherapy before surgery (to shrink tumors), after surgery (to eliminate remaining cancer cells), or both. These studies aim to identify treatment strategies that provide the best chance of long-term survival while maintaining acceptable quality of life.

Emerging Technologies and Approaches

Beyond drugs, researchers are investigating other innovative approaches. Some trials explore using sophisticated imaging techniques to better identify which tumors will respond to specific treatments, potentially allowing more personalized treatment selection. Others test new radiation delivery methods that can more precisely target tumors while sparing healthy tissue.

Investigators are also studying whether certain biomarkers—measurable indicators found in blood, tumor tissue, or other samples—can predict treatment response or resistance. If successful, these biomarker-based strategies could help match each patient with the treatments most likely to help them, avoiding ineffective therapies and their associated side effects.

Most Common Treatment Methods

• Surgery
  • Partial hepatectomy to remove the portion of liver containing cancer along with surrounding healthy tissue
  • Complete liver transplantation, replacing the entire diseased liver with a healthy donor organ in carefully selected patients
  • Surgical removal of bile ducts, gallbladder, or portions of pancreas depending on tumor location
• Ablation Therapy
  • Radiofrequency ablation using high-energy radio waves delivered through needles to heat and destroy tumors
  • Microwave ablation applying microwave energy to create tumor-destroying temperatures
  • Percutaneous ethanol injection delivering pure alcohol directly into tumors to kill cancer cells
  • Cryoablation freezing tumor tissue with extreme cold
• Embolization Therapy
  • Transarterial embolization (TAE) blocking blood flow to tumors through the hepatic artery
  • Transarterial chemoembolization (TACE) combining artery blockage with targeted chemotherapy delivery
• Radiation Therapy
  • External beam radiation using advanced techniques to minimize damage to healthy tissue
  • Selective internal radiation therapy (SIRT) delivering radioactive beads directly into tumor blood vessels
• Chemotherapy
  • Systemic chemotherapy drugs given intravenously or orally to treat cancer throughout the body
  • Regional chemotherapy delivered directly to the liver through arterial infusion
• Targeted Therapy
  • Medications that block specific molecular signals promoting tumor growth
  • Drugs that interfere with new blood vessel formation that tumors need to grow
  • Agents targeting specific genetic mutations found in some hepatobiliary cancers
• Immunotherapy
  • Checkpoint inhibitors that help the immune system recognize and attack cancer cells
  • Combination immunotherapy approaches being tested in clinical trials

Surveillance and Monitoring

For very small liver lesions detected during screening, doctors sometimes recommend a surveillance approach rather than immediate treatment. This involves closely monitoring the lesion with regular imaging tests, typically every three months. Treatment begins only if tests show that the lesion is growing or changing in ways that suggest it’s becoming more aggressive. This careful watching approach helps avoid treating benign lesions or very slow-growing cancers that might never cause problems, while still allowing prompt treatment if necessary.^[9]

Follow-up Care After Treatment

After completing initial treatment for hepatobiliary cancer, patients require ongoing follow-up care. Regular appointments typically include physical examinations, blood tests to check liver function and tumor markers, and imaging scans to look for any signs of cancer recurrence. The frequency of these follow-up visits is usually highest in the first year after treatment and may gradually decrease over time if no problems are detected.

Follow-up care serves multiple purposes: detecting cancer recurrence early when it may still be treatable, managing any long-term treatment side effects, monitoring and treating underlying liver disease that may have contributed to the cancer’s development, and providing support for the physical and emotional challenges of living after cancer.^[16]

During follow-up, healthcare teams also address lifestyle factors that can affect liver health and overall well-being. This might include recommendations about diet, alcohol avoidance, maintaining healthy weight, managing related conditions such as hepatitis or diabetes, and strategies for coping with the psychological impact of cancer diagnosis and treatment.